← SynDRA
GSK2982772
SynDRA canonical compound SYN0039247 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | RIPK1 |
|---|
| Mechanism of action | RIPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- RIPK1 INHIBITOR
- Receptor-interacting serine/threonine-protein kinase 1 inhibitor
- RIPK inhibitor
Cross-references
Synonyms
- 7MJ
- CPD 5
- GSK-2982772
- LYPAFUINURXJSG-AWEZNQCLSA-N
- UNII-T5W3M0VO9B
- T5W3M0VO9B
- GSK 2982772
- (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide
- GTPL9554
- SCHEMBL15956219
- MolPort-044-830-634
- s8484
- AKOS030528033
- compound 5 [PMID: 28151659]
- ACN-041458
- CS-6899
- AS-35128
- AC-29894
- HY-101760
- J3.650.802G
- 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
- 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr
- RefChem:922551
- MFCD30828708
- C20H19N5O3
- orb1300025
- SCHEMBL21678862
- SCHEMBL25801152
- SCHEMBL29355591
- GSK'772
- GLXC-10561
- EX-A2558
- BDBM50233225
- AKOS037643747
- CCG-268376
- EBC-218025
- GSK 2982772 [WHO-DD]
- GSK2982772?
Look up GSK2982772 in the interactive SynDRA portal →